179 related articles for article (PubMed ID: 8001028)
1. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.
McAveney KM; Gomella LG; Lattime EC
Cancer Immunol Immunother; 1994 Dec; 39(6):401-6. PubMed ID: 8001028
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.
Nadler R; Luo Y; Zhao W; Ritchey JK; Austin JC; Cohen MB; O'Donnell MA; Ratliff TL
Clin Exp Immunol; 2003 Feb; 131(2):206-16. PubMed ID: 12562379
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M; Ramos KL; Andrade PM
J Exp Clin Cancer Res; 2008 Nov; 27(1):78. PubMed ID: 19040745
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.
Shin JS; Park JH; Kim JD; Lee JM; Kim SJ
Clin Exp Immunol; 1995 Apr; 100(1):26-31. PubMed ID: 7697918
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma.
Arnold J; de Boer EC; O'Donnell MA; Böhle A; Brandau S
J Immunother; 2004; 27(2):116-23. PubMed ID: 14770083
[TBL] [Abstract][Full Text] [Related]
7. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
8. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
10. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
[TBL] [Abstract][Full Text] [Related]
11. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
13. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
[TBL] [Abstract][Full Text] [Related]
14. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin.
Sander B; Damm O; Gustafsson B; Andersson U; Håkansson L
J Urol; 1996 Aug; 156(2 Pt 1):536-41. PubMed ID: 8683732
[TBL] [Abstract][Full Text] [Related]
15. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
16. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.
Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K
Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
18. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).
Saban MR; Simpson C; Davis C; Wallis G; Knowlton N; Frank MB; Centola M; Gallucci RM; Saban R
BMC Immunol; 2007 May; 8():6. PubMed ID: 17506885
[TBL] [Abstract][Full Text] [Related]
19. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
